News -CureApp, Inc.

  Toward Dissemination of Digital Therapeutics CureApp and Teijin Pharma Sign Agreement for Joint Marketing and Sales of Prescription Digital Therapeutic App for Hypertension Teijin Pharma Limited (Headquarters: Chiyoda-ku, Tokyo, President: Masaki Taneda, hereinafter Teijin Pharma) and CureApp, Inc. ( Headquarters: Chuo-ku, Tokyo, President: Kohta Satake, hereinafter CureApp) have concluded a joint marketing and sales agreement (hereinafter, joint agreement) for the "Prescription Digital Therapeutic App for Hypertension" (hereinafter, CureApp HT) as of April 1st. Through this partnership, we aim to expand the use of CureApp HT, which supports the lifestyle modifications that are a prerequisite to any type of hypertension treatment. Further, through the distribution of digital therapeutics (DTx) *1 , the two companies aspire to address unmet medical needs. *1 Digital therapeutics: medical devices that have been approved by regulatory authorities for their therapeutic effects,

CureApp Inc. has ranked in the ” World's Best Digital Health Companies 2024” list   CureApp Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake) is pleased to announce that it has been selected as one of the ”World's Best Digital Health Companies 2024”. About World’s Best Digital Health Companies 2024 T his is the first survey conducted jointly by U.S. weekly magazine Newsweek and data intelligence platform Statista to identify new services and technologies that are transforming the digital health market. The survey included nearly 400 companies from 35 countries worldwide. For more details, please visit: https://www.newsweek.com/rankings/worlds-best-digital-health-companies-2024 Comments by Kota Satake, CEO, CureApp The size of the digital health market has grown rapidly both domestically and internationally, more than we imagined when we founded CureApp 10 years ago. Many companies and research institutions are advancing research and development all over the world. We are ve

World’s first real-world data on the hypotensive effects of digital therapeutics Introducing a smart antihypertensive therapy using a “hypertension digital therapeutic app” covered by insurance   Allows for continuous use in patients aged 65 years and up, reducing morning systolic blood pressure by -8.8mmHg after 12 weeks CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake; hereafter, “the Company”) presented* 1 the results of a study into the hypotensive effects in patients undergoing a smart antihypertensive therapy using a hypertension digital therapeutic app (hereafter “DTx app”) at The 45th Annual Scientific Meeting of the Japanese Society of Hypertension.  　Analysis results based on blood pressure data entered into the DTx app prescribed at medical institutions nationwide show a change in systolic blood pressure after 12 weeks across the whole population* 2 of -8.8mmHg on waking (morning blood pressure), and -8.5mmHg before sleeping (bedtime blood pressure). The study

　CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake, hereafter, “the Company”) entered into a license agreement with Sawai Group Holdings Co., Ltd. (Head Office: Yodogawa-ku, Osaka; Representative Director and President: Kazuhiko Sueyoshi, hereafter, “the Sawai Group”) for the development and marketing of a DTx solution (hereafter, “the app”) in the NASH (Non-Alcoholic Steatohepatitis) field. 　With the conclusion of this agreement, the Sawai Group obtains exclusive rights concerning the development and marketing of the app indicated for the treatment of NASH. 　Under this agreement, the Company is set to receive up to 10.5 billion yen in total in the form of a lump sum contractual payment, and as additional payments for milestones reached based on future clinical development progress and sales targets. After launch, the Company plans to introduce the app at medical institutions via its proprietary app prescription service (APS). *1 Abbreviation of Digital Therapeutics. Softwa

  Strategic growth investment in CureApp to support the rollout of its hypertension app and advance its new development pipeline, as digital therapeutics gain traction in Japan Tokyo, Japan, August 16, 2022 – Global investment firm Carlyle (NASDAQ:CG) today announced a strategic partnership with CureApp, Inc., a leading Japanese medical technology (“MedTech”) company and prescription digital therapeutics provider, through an acquisition of a significant minority stake in the company. The investment is part of CureApp’s Series G funding, whereby Carlyle will be investing JPY 7 billion in the company. This brings the total amount of capital raised by CureApp to approximately JPY 13.4 billion. Carlyle will have one board seat as part of the transaction. Founded in 2014 by two physicians, CureApp is one of Japan’s fastest-growing MedTech companies specializing in the research and development of prescription and non-prescription digital therapeutics. Its hypertension prescription digital

World’s First Medical Device Regulatory Approval of Digital Therapeutic App for Hypertension Mental and Behavioral Approaches to Lifestyle Modification 　CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake) was notified by the Ministry of Health, Labour and Welfare on April 26, 2022 that the company had received the medical device regulatory approval of an digital therapeutic app for Hypertension. This marks the first time a standalone software app supporting doctors and patients has received medical device regulatory approval in Japan, and is the first app addressing hypertension to be approved in the world. Preparations are now underway to receive reimbursement and launch the app in 2022. Hypertension  　 　Lifestyle modification is a vitally important part of treating essential hypertension, regardless of blood pressure classification. However, lifestyle modifications are dependent on the patient’s mindset and motivation, and workplace and home environment, and are difficult